Member Info for Krone

We believe our two TYK2/JAK1 inhibitors have the potential to address unmet needs in autoimmune diseases and cancer, through a novel mechanism that is clearly gaining increasing interest from both the pharmaceutical industry and financial investors.
The sp in no way reflects increasing interest from financial investors. The EGM must address this matter and specifically what Parker has done since joining Sareum to increase the level of institutional investment I.e. how many new IIs and how many shares. Thus far there is no evidence that Parker has added any value whatsoever, the contrary!

Thoth - would you share the detail of your communication with Tim, redacted if necessary, so we are all on the same page. Thanks

Thoth - I share your serious and legitimate concers.

Potnak - do you seriously think investors have the appetite for a further raise....surely not given the way sp has gone since the last one. Negative sentiments exacerbated by the lousy communications from the bod serve only increase the importance of an early EGM. The bod have 6 days to respond to Thoth2’s end of August deadline!!

Potnak - my point is that Sareum are themselves fuelling the speculation.

The scale of the deals and sales delivered/forecast for these candidates and products targeting TYK2 and related JAK family members gives Sareum confidence in the exciting, high value market opportunity for SDC-1801

Potnak - In fairness, responsibility for the speculation regarding potential values has been fuelled at least in part by Sareum - http://www.sareum.com/files/2215/3838/2124/Sareum_2018_FY_Results_.pdf
TD-1473 (a pan-JAK inhibitor) – licensed by Janssen from Theravance (2018) at the end of Phase 1 studies for $100M cash up-front, up to $900M in milestone payments, plus royalties*
? Filgotinib (JAK1 inhibitor) – licensed by Gilead from Galapagos (2015) at the end of Phase 2 trials for $300M cash and $425M equity investment up-front, up to $1,350M in milestone payments, plus 20%+ royalties*
? Undisclosed TYK2 inhibitor (plus other assets) – Celgene formed an alliance with Nimbus Therapeutics (2017) in preclinical stage for undisclosed up-front and milestone payments
Approved products targeting the JAK family with blockbuster sales potential, despite warnings based on side effects related to JAK2/JAK3 activity, include:
? Xeljanz® tofacitinib (Pfizer) (JAK1/JAK3 inhibitor) - approved for rheumatoid and psoriatic arthritis and ulcerative colitis, with 2017 sales of $1.35Bn*, despite black box warnings for serious infections and lymphoma
? Olumiant® baricitinib (Eli Lilly) (JAK1/JAK2 inhibitor) – approved from rheumatoid arthritis, with expected peak sales of approximately $1Bn*, but with black box warnings for serious infections, lymphoma and thrombosis
? Jakafi® ruxolitinib (Incyte/Novartis) – approved for myelofibrosis and polycythemia vera (a type of blood cancer) with 2017 sales of $1.1Bn* despite warnings of infections and blood cell counts
The scale of the deals and sales delivered/forecast for these candidates and products targeting TYK2 and related JAK family members gives Sareum confidence in the exciting, high value market opportunity for SDC-1801

OK thanks

Has time acknowledged/responded to your email regarding forthcoming EGM?

WTF is an ‘advisory boutique’? Sounds like some of Parker’s cronies....

Suggest change of chairman should also be seriously considered!

RMM - hear hear!!

It will be interesting to see what reference Nick Glover makes re 737 tomorrow. Can he make the situation any worse?

It’s generally agreed that the science is cutting edge with an increasing body of robust empirical evidence, however in the absence of a BoD with the commercial nous and wherewithal to vigorously progress the molecules towards commercialisation it’s not worth a lot.

Suggest the timeline for a response from Tim was overly generous. Given the ongoing slide and implications in respect of the SRRA situation, assurances are needed asa matter of urgency i.e. cop Monday. Those with >28m hold more shares than 6 of the institutional investors listed on FT.

Trek - don’t Sierra simply need to be told that the terms of the existing agreement will be enforced, no ifs or buts. An agreement is an agreement!

Enough to pay NG’s $1m+ remuneration package but not monies contractually owing via milestones

Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib

- Up to $15 million available in three $5 million tranches; additional $25 million potentially available -
VANCOUVER, Aug. 22, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it has obtained a debt facility from Silicon Valley Bank......
"This credit facility provides us with the option to access minimally dilutive capital rapidly and incrementally as needed to advance momelotinib, while helping to ensure we remain well capitalized to prosecute our robust development program for SRA737 and commence the clinical program for SRA141," said Dr. Nick Glover, President and CEO of Sierra Oncology. "With this facility, combined with our cash position of approximately $125 million as at June 30, 2018, we believe we have sufficient resources to deliver on key milestones across all three programs."

Happy to tweet about MGC cannabis.....unbelievable!!!

Thoth2- what will ICR/CRT’s view be on this. Won’t they want to get this moving ASAP given the evidenced potential for anogenital. They’ll have the will and the clout to get this sorted surely.

This doesn’t look at all good!!! Sierra effectively ditching 737. Now Parker show is what you’re made of!